Assessing the Feasibility of Replacing Standard-Dose Bacillus Calmette-Guérin Immunotherapy with Other Intravesical Instillation Therapies in Bladder Cancer Patients: A Network Meta-Analysis.

摘要: Background: Bacillus Calmette–Guerin (BCG) immunotherapy plays a key role in patients with bladder cancer. The shortage of intravesical BCG has motivated researchers to seek alternatives equivalent efficacy If other alternative agents have compared BCG, then it may be feasible replace standard options. Methods: We searched all relevant evidence multiple sources and data was extracted from included studies. Conventional network meta-analysis were conducted so that pooled odds ratios (ORs) for the event tumor recurrence progression can computed. relative different instillation procedures computed by their 95% confidence or creditable intervals. Besides, several model assumptions evaluated our analysis. Results: Three potential preventing recurrence: standard-dose (BCG_SD), Epirubicin (EPI) Mitomycin C (MMC) (ORs < 1). Patients SD also exhibited decreased risk those EPI. No significant difference detected between treated BCG_ low-dose (BCG_LD). Results SUCRA indicated BCG_EPI, MMC had higher rankings respect progression. Conclusions: SD, EPI established postoperative BC patients. not significantly reduced if dose lower level. However, there is no consensus suggesting replaced alternating sequentially combined therapies.